You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
According to the Atlantic, the Centers for Disease Control and Prevention and several US states are combining viral and antibody testing data for SARS-CoV-2, making that data hard to parse.
The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.
Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The company is working to develop another lab-based serology test to detect IgM antibodies in people who have already had the virus.
The firms plan to discover and develop fully human neutralizing antibodies that target the SARS-CoV-2 virus, combining Adaptive's and Amgen's respective expertise.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.